Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Christos Stelios Karapetis"'
Autor:
Nick Pavlakis, Gary Tincknell, Lisi Elizabeth Lim, Kei Muro, Radka Obermannova, Sylvie Lorenzen, Yu Jo Chua, Chris Jackson, Christos Stelios Karapetis, Timothy Price, Lorraine Chantrill, Eva Segelov, Florian Lordick
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 14 (2022)
Gastric carcinoma and gastro-oesophageal junction (GC/GEJ) carcinoma remain a significant global problem, with patients presenting with symptoms often found to have advanced or metastatic disease. Treatment options for these patients have broadened i
Externí odkaz:
https://doaj.org/article/b9de93c28fba431191be44e8a40c49a6
Autor:
M. Nazim Abbas, Myron Klevansky, Bogda Koczwara, Amitesh Chandra Roy, Shawgi Sukumaran, Sina Vatandoust, Christos Stelios Karapetis
Publikováno v:
Cancer Reports, Vol 5, Iss 3, Pp n/a-n/a (2022)
Abstract Background Nivolumab improves disease control and survival in advanced NSCLC in patients with good performance status (PS), but there is limited data on its efficacy in patients with poor PS. Aim Primary objective of the study was to evaluat
Externí odkaz:
https://doaj.org/article/780ffd93d8ec4f52b293d9ebe91990d5
Autor:
Michael B. Jameson, Kirsten Gormly, David Espinoza, Wendy Hague, Gholamreza Asghari, Grahame Mark Jeffery, Timothy Jay Price, Christos Stelios Karapetis, Michael Arendse, James Armstrong, John Childs, Frank A. Frizelle, Sam Ngan, Andrew Stevenson, Martinus Oostendorp, Stephen P. Ackland
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-12 (2019)
Abstract Background Retrospective studies show improved outcomes in colorectal cancer patients if taking statins, including overall survival, pathological response of rectal cancer to preoperative chemoradiotherapy (pCRT), and reduced acute and late
Externí odkaz:
https://doaj.org/article/631cd481e261422aa5a9a4ae454d866e
Autor:
Hilary Laura Martin, Shahid Ullah, Nazim Abbas, Alex Scott‐Hoy, Ganessan Kichenadasse, Christos Stelios Karapetis, Amitesh Roy, Shawgi Sukumaran, David M Ross, Muhammad Adnan Khattak, Bogda Koczwara
Publikováno v:
Cancer Reports, Vol 4, Iss 3, Pp n/a-n/a (2021)
Abstract Background Chemotherapy can cause premature menopause which may result in adverse effects such as fertility loss, osteoporosis, cardiovascular disease and menopausal symptoms. It is thus very important that women are provided with accurate i
Externí odkaz:
https://doaj.org/article/f10b59e518164f45af49712da2dd44f0
Autor:
Christos Stelios Karapetis, Sonja Klebe, Ashleigh Jean Hocking, Alexandra L Farrall, Sarah Newhouse, Peter Sordillo, Kim Greco, Brendan Dougherty
Publikováno v:
BMJ Open, Vol 11, Iss 3 (2021)
Introduction This is a phase 1, open-label, single-centre, uncontrolled, dose-escalation study to evaluate the feasibility, tolerability and pharmacokinetic profiles of a single dose of liposomal curcumin, administered via an existing tunnelled indwe
Externí odkaz:
https://doaj.org/article/c3606f7bea21440abdb05469e84941ee
Autor:
Amitesh Chandra Roy, M. Nazim Abbas, Timothy Jay Price, Nimit Singhal, Sina Vatandoust, John Leung, Ganessan Kichenadasse, Bogda Koczwara, Shawgi Sukumaran, Rajiv Kumar, Richard Woodman, Alex Scott-Hoy, Christos Stelios Karapetis
Publikováno v:
Pancreas. 51:490-495
Nab-paclitaxel has radiosensitizing antitumor efficacy in pancreatic cancer. We aimed to establish maximum tolerated dose (MTD) of nab-paclitaxel with radiotherapy in unresectable locally advanced pancreatic cancer.In a phase I dose escalation trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c695571645ebaaaa0dfc16ea1e7c7843
https://doi.org/10.1097/mpa.0000000000002065
https://doi.org/10.1097/mpa.0000000000002065
Autor:
Joao Paulo Solar Vasconcelos, Nan Chen, Dongsheng Tu, Stephanie Yasmin Brule, Rachel Anne Goodwin, Derek J. Jonker, Timothy Jay Price, John Raymond Zalcberg, Malcolm J. Moore, Christos Stelios Karapetis, Lillian L. Siu, Jeremy David Shapiro, John Simes, Christopher J. O'Callaghan, Jonathan M. Loree
Publikováno v:
Journal of Clinical Oncology. 41:124-124
124 Background: Primary tumour location is predictive of anti-EGFR benefit and prognostic in metastatic colorectal cancer (mCRC). Transverse colon cancers are often categorized as right sided, but the optimal cut point is unclear. Canadian Cancer Tri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::79c40da228df58a3e4927afc0b947b72
https://doi.org/10.1200/jco.2023.41.4_suppl.124
https://doi.org/10.1200/jco.2023.41.4_suppl.124
Autor:
Tharani Krishnan, Shahid Ullah, Cynthia Piantadosi, Christos Stelios Karapetis, Amanda Rose Townsend, Amitesh Roy, Barbara Geerinckx, Guy Maddern, David Roder, Rob Padbury, Timothy Price
Publikováno v:
Journal of Clinical Oncology. 41:42-42
42 Background: The anti-EGFR monoclonal antibodies panitumumab (Pmab) and cetuximab (Cmab) and the anti-VEGF antibody bevacizumab (bev) have demonstrated clinical efficacy in mCRC in combination with first-line chemotherapy. Clinical and molecular ch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8d94e6244415bbbc348fca3b7e4c9243
https://doi.org/10.1200/jco.2023.41.4_suppl.42
https://doi.org/10.1200/jco.2023.41.4_suppl.42
Autor:
Anas, Alawawdeh, Cynthia, Piantadosi, Amanda Rose, Townsend, Christos Stelios, Karapetis, Rob, Padbury, Amitesh Chandra, Roy, James, Moore, Guy, Maddern, David, Roder, Annabelle, Smith, Timothy Jay, Price
Publikováno v:
Targeted oncology. 17(1)
Effective targeting of RAS mutations has proven elusive until recently. Novel agents directly targeting KRAS G12C have shown promise in early-phase clinical trials that included patients with metastatic colorectal cancer. Prior reports have suggested
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::283e640aacb3567cf8c37391ef988e96
https://pubmed.ncbi.nlm.nih.gov/34822070
https://pubmed.ncbi.nlm.nih.gov/34822070
Autor:
Arjun Gupta, Christopher J. O'Callaghan, Liting Zhu, Derek J. Jonker, Ralph Wong, Bruce Colwell, Malcolm J Moore, Christos Stelios Karapetis, Niall C Tebbutt, Jeremy David Shapiro, Dongsheng Tu, Christopher M. Booth
Publikováno v:
Journal of Clinical Oncology. 40:248-248
248 Background: Most individual treatments for advanced cancer are associated with modest survival benefits. The time spent in pursuing these treatments can be substantial. We have previously developed a pragmatic and patient-centered metric of these
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::71fcc0931e194ea815f58254bd2fcf6e
https://doi.org/10.1200/jco.2022.40.28_suppl.248
https://doi.org/10.1200/jco.2022.40.28_suppl.248